Rituximab for chronic lymphocytic leukemia

Expert Opinion on Biological Therapy

Volumn 12, Issue 4, 2012, Pages 503-515

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Autoimmune cytopenia; Cladribine; CLL; First line; Fludarabine; Maintenance; Monoclonal antibody; Pentostatin; R FC; Refractory; Relapsed; Rituximab

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; LUMILIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; PENTOSTATIN; RITUXIMAB;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DATA BASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOXICITY; HUMAN; INFORMATION RETRIEVAL; LEUKEMIA RELAPSE; LOW DRUG DOSE; MEDLINE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); RISK; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE;

EID: 84858664440     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.665444     Document Type: Article

References (92)

1. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445-76
2. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74
3. Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type 1 and 2 monoclonal antibodies. Semin Hematol 2010;47:107-14
4. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003;278:42427-34 (Pubitemid 37310514)
5. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45 (Pubitemid 24030569)
6. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 2001;12(Suppl 2):1-4
7. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008;13:954-66
8. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 2000;95:3900-8 (Pubitemid 30412866)
9. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52 (Pubitemid 36139378)
10. Manches O, Lui G, Chapero L, et al. In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949-54 (Pubitemid 36139365)
11. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal tibodies. Blood 1998;91:1644-52 (Pubitemid 28110329)
12. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999;58:79-88
13. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43 (Pubitemid 34525569)
14. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008;13:954-66
15. Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007;26:6184-9
16. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDECC238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 2002;87:33-43 (Pubitemid 34101111)
17. Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 2004;13:279-87 (Pubitemid 38834460)
18. CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J NatlCancer Inst 1999;91:861-8
19. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002;16:1015-27 (Pubitemid 34618840)
20. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7
21. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-9
22. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-91 (Pubitemid 43156283)
23. Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a Phase III randomized study by the Polish Adult Leukemia Group (PALGCLL3 Study). J Clin Oncol 2010;28:1861-9
24. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase III trial. Lancet 2010;376:1164-74
25. Robak T, Dmoszynska A, Solal-Celigny A, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previouslytreated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-65
26. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-23 (Pubitemid 32707998)
27. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-51 (Pubitemid 46638587)
28. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-31
29. Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999;62:76-82 (Pubitemid 29071265)
30. Schulz H, Klein SK, Rehwald U, et al. Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-20 (Pubitemid 35217057)
31. Del Poeta G, DelPrincipe MI, Consalvo MA, et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia. Cancer 2005;104:2743-52 (Pubitemid 41798284)
32. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase II study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia results from Cancer and Leukemia Group B 9712 (CALG B9712). Blood 2003;101:6-14 (Pubitemid 36025880)
33. Byrd J, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53 (Pubitemid 40053062)
34. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term followup of CALGB study 9712. J Clin Oncol 2011;29:1349-55
35. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88 (Pubitemid 46211313)
36. Tsimberidou AM, Tam C, Abruzzo LV, et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373-80
37. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:498-503
38. Robak T. How to improve the treatment outcome in chronic lymphocytic leukemia? Leuk Res 2010;34:272-5
39. Faderl S, Wierda W, O'Brien S, et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL
40. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active hemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-84
41. Bosch F, Abrisque P, Villamor N, et al. Rituximab maintenance in patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (R-FCM): final results of a multicenter phase II trial on behalf of the Spanish CLL Study Group (GELLC) [abstract 293]. Blood 2011;118:136
42. Parikh SA, Keating MJ, O'Brien S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011;118:2062-8
43. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-11 (Pubitemid 46105933)
44. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007;109:2291-8 (Pubitemid 46801560)
45. Reynolds C, Di Bella N, Lyons RM, et al. A phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs [Epub ahead of print, 16 September 2011; doi: 10.1007/s10637-011-9737-y]
46. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009;23:1779-89
47. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract 205]. Blood 2009;114:89
48. German CLL Study Group, National Cancer Institute (NCI). Fludarabine, Cyclophosphamide, and Rituximab or Bendamustine and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia ClinicalTrials.gov NCT00769522. Available from: http://clinicaltrials.gov/ ct2/results?term=NCT00769522
49. Herold M, Schulze A, Hartwig K, Anger G. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab. Ann Hematol 2000;79:332-5 (Pubitemid 30349027)
50. Itala M, Geisler CH, Kimby E, et al. Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002;69:129-34 (Pubitemid 35335149)
51. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70 (Pubitemid 32366970)
52. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64 (Pubitemid 32366969)
53. Wiernik PH, Adiga GU. Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. Curr Med Res Opin 2011;27:1987-93
54. Robak T, Lech-Maranda E, Robak P. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2010;10:1529-43
55. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-8 (Pubitemid 46211312)
56. Dornan D, Spleiss O, Yeh RF, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 2010;116:4212-22
57. Wierda WG, O'Brien SM, Faderl SH, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [abstract 31]. Blood 2006;108:14a
58. Hillmen P, Cohen DR, Cocks K, et al. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. Br J Haematol 2011;152:570-8
59. Byrd JC, Kipps TJ, Flinn IW, et al. Phase I/II study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115:489-95
60. Biogen Idec. Lumiliximab With Fludarabine, Cyclophosphamide, and rituximab (FCR) versus fcr alone in subjects with relapsed chronic lymphocytic leukemia (CLL) (LUCID). ClinicalTrials.gov NCT00391066. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00391066
61. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide and rituximab is an active well tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575-81 (Pubitemid 46638781)
62. Robak T, Smolewski P, Cebula B, et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006;107:1542-50 (Pubitemid 44546915)
63. Robak T, Smolewski P, Cebula B, et al. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007;79:107-13 (Pubitemid 47063264)
64. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559-66
65. Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:2269-73 (Pubitemid 39504321)
66. Faderl S, Ferrajoli A, Wierda W, et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 2010;116:2360-5
67. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-53
68. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412-17 (Pubitemid 350253473)
69. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase III, randomised controlled trial. Lancet 2010;377:42-51
70. O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9:22-3
71. Keating GM. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. BioDrugs 2011;25:55-61
72. Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008;112:119-28
73. Srock S, Schriever F, Neubauer A, et al. Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leuk Lymphoma 2007;48:905-11 (Pubitemid 47161562)
74. Hodgson K, Ferrer G, Pereira A, et al. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 2011;154:14-22
75. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004;72:79-88 (Pubitemid 38161156)
76. Iannitto E, Ammatuna E, Marino C, et al. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody. Blood 2002;99:1096-7 (Pubitemid 34525581)
77. Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003;44:1951-5 (Pubitemid 37369630)
78. Gupta N, Kuvaru S, Patel D, et al. Rituximab based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-5 (Pubitemid 35203453)
79. Trape G, Fianchi L, Lai M, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003;88:223-5 (Pubitemid 37101503)
80. Kaufman M, Limaye SA, Driscoll N, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:892-9
81. Rossignol J, Michallet AS, Oberic L, et al. Rituximab- cyclophosphamidedexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2011;25:473-8
82. Michallet AS, Rossignol J, Cazin B, Ysebaert L. Rituximabcyclophosphamide- dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1401-3
83. Bowen DA, Call TG, Shanafelt TD, et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma 2010;51:620-7
84. D'Arena G, Capalbo S, Laurenti L, et al. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. Eur J Haematol 2010;85:502-7
85. Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002;100:2260-2 (Pubitemid 35001267)
86. Niitsu N, Hagiwara Y, Tanae K, et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010;28:5097-100
87. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy - rare but there! Leuk Lymphoma. 2009;50:1083-95
88. Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2011;50:2297-305
89. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-19 (Pubitemid 47502698)
90. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008;76:449-53
91. Robak T, Robak P, Smolewski P. The evaluation and optimal use of rituximab in lymphoid malignancies. Blood Lymphat Cancer Targets Ther 2012;2:1-16
92. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011;25:13-25